Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies

NCT03037645 is registered in ClinicalTrials.gov with Sunesis Pharmaceuticals as lead sponsor.

NCT NCT03037645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03037645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies
Lead sponsor
Sunesis Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
April 28, 2017
Completion date
August 31, 2020
Enrollment
39 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, lymphoplasmacytoid lymphoma, mantle-cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, waldenstrom macroglobulinemia